Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vactosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 known ✓ | P36897 | 20/20 | 0.87 |
| ▸ | MAPK14 | Q16539 | 17/20 | 0.87 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.87 |
| ▸ | TGFB1 | P01137 | 1/20 | 0.87 |
| ▸ | KDR | P35968 | 1/20 | 0.87 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vactosertib SCHEMBL30568127 | 1.00 | TGFBR1 (0.87) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL29493095 | 0.93 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL250076 | 0.93 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL29508696 | 0.93 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL29352498 | 0.93 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL248684 | 0.87 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL22910768 | 0.87 | TGFBR1 (0.67) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL20602767 | 0.87 | TGFBR1 (0.89) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Hydrochloric Acid SCHEMBL22263453 | 0.86 | TGFBR1 (0.87) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL23330024 | 0.85 | TGFBR1 (0.68) | TGFBR1MAPK14RIPK2TGFB1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303568-A1 | INTERMEDIATE USEFUL FOR THE SYNTHESIS OF TGF-BETA INHIBITORS AND A METHOD OF PREPARING TGF-BETA INHIBITORS USING THE SAME | MEDPACTO INC. (KR) | 2023-09-28 | — | — | US | disclosed |
| US-20230303568-A1 | INTERMEDIATE USEFUL FOR THE SYNTHESIS OF TGF-BETA INHIBITORS AND A METHOD OF PREPARING TGF-BETA INHIBITORS USING THE SAME | MEDPACTO INC. (KR) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303568-A1 | INTERMEDIATE USEFUL FOR THE SYNTHESIS OF TGF-BETA INHIBITORS AND A METHOD OF PREPARING TGF-BETA INHIBITORS USING THE SAME | TGFB1, TGFBR1, TGFB2 | TGFBR1 2/4885MAPK14 1741/4885RIPK2 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.